95 related articles for article (PubMed ID: 21593444)
1. Long-term efficacy of deferasirox in preventing cardiovascular complications in the iron-overloaded gerbil.
Al-Rousan RM; Manzoor K; Paturi S; Arvapalli RK; Laurino JP; Darnon L; Walker EM; Blough ER
J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):117-25. PubMed ID: 21593444
[TBL] [Abstract][Full Text] [Related]
2. Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil.
Al-Rousan RM; Paturi S; Laurino JP; Kakarla SK; Gutta AK; Walker EM; Blough ER
Am J Hematol; 2009 Sep; 84(9):565-70. PubMed ID: 19650117
[TBL] [Abstract][Full Text] [Related]
3. Acetaminophen protects against iron-induced cardiac damage in gerbils.
Walker EM; Epling CP; Parris C; Cansino S; Ghosh P; Desai DH; Morrison RG; Wright GL; Wehner P; Mangiarua EI; Walker SM; Blough ER
Ann Clin Lab Sci; 2007; 37(1):22-33. PubMed ID: 17311866
[TBL] [Abstract][Full Text] [Related]
4. Deferasirox protects against iron-induced hepatic injury in Mongolian gerbil.
Al-Rousan RM; Rice KM; Katta A; Laurino J; Walker EM; Wu M; Triest WE; Blough ER
Transl Res; 2011 Jun; 157(6):368-77. PubMed ID: 21575921
[TBL] [Abstract][Full Text] [Related]
5. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil.
Wood JC; Otto-Duessel M; Gonzalez I; Aguilar MI; Shimada H; Nick H; Nelson M; Moats R
Transl Res; 2006 Nov; 148(5):272-80. PubMed ID: 17145573
[TBL] [Abstract][Full Text] [Related]
6. Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy.
Yang T; Brittenham GM; Dong WQ; Levy MN; Obejero-Paz CA; Kuryshev YA; Brown AM
J Lab Clin Med; 2003 Nov; 142(5):332-40. PubMed ID: 14647037
[TBL] [Abstract][Full Text] [Related]
7. Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy.
Otto-Duessel M; Aguilar M; Nick H; Moats R; Wood JC
Exp Hematol; 2007 Jul; 35(7):1069-73. PubMed ID: 17588475
[TBL] [Abstract][Full Text] [Related]
8. Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy.
Obejero-Paz CA; Yang T; Dong WQ; Levy MN; Brittenham GM; Kuryshev YA; Brown AM
J Lab Clin Med; 2003 Feb; 141(2):121-30. PubMed ID: 12577048
[TBL] [Abstract][Full Text] [Related]
9. Acetaminophen combinations protect against iron-induced cardiac damage in gerbils.
Walker EM; Morrison RG; Dornon L; Laurino JP; Walker SM; Studeny M; Wehner PS; Rice KM; Wu M; Blough ER
Ann Clin Lab Sci; 2009; 39(4):378-85. PubMed ID: 19880766
[TBL] [Abstract][Full Text] [Related]
10. Iron-induced cardiac damage: role of apoptosis and deferasirox intervention.
Wang Y; Wu M; Al-Rousan R; Liu H; Fannin J; Paturi S; Arvapalli RK; Katta A; Kakarla SK; Rice KM; Triest WE; Blough ER
J Pharmacol Exp Ther; 2011 Jan; 336(1):56-63. PubMed ID: 20947636
[TBL] [Abstract][Full Text] [Related]
11. Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice.
Kumfu S; Chattipakorn SC; Fucharoen S; Chattipakorn N
Exp Physiol; 2016 Apr; 101(4):521-39. PubMed ID: 26824522
[TBL] [Abstract][Full Text] [Related]
12. Optical mapping reveals conduction slowing and impulse block in iron-overload cardiomyopathy.
Laurita KR; Chuck ET; Yang T; Dong WQ; Kuryshev YA; Brittenham GM; Rosenbaum DS; Brown AM
J Lab Clin Med; 2003 Aug; 142(2):83-9. PubMed ID: 12960954
[TBL] [Abstract][Full Text] [Related]
13. Treatment of iron overload in thalassemia.
Cianciulli P
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
[TBL] [Abstract][Full Text] [Related]
14. Current and future treatment strategies for iron overload cardiomyopathy.
Wongjaikam S; Kumfu S; Chattipakorn SC; Fucharoen S; Chattipakorn N
Eur J Pharmacol; 2015 Oct; 765():86-93. PubMed ID: 26291660
[TBL] [Abstract][Full Text] [Related]
15. Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats.
Wongjaikam S; Kumfu S; Khamseekaew J; Sripetchwandee J; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N
PLoS One; 2016; 11(7):e0159414. PubMed ID: 27428732
[TBL] [Abstract][Full Text] [Related]
16. Deferasirox: for iron overload: only a third-line option.
Prescrire Int; 2007 Oct; 16(91):196. PubMed ID: 17929382
[TBL] [Abstract][Full Text] [Related]
17. Deferasirox decreases age-associated iron accumulation in the aging F344XBN rat heart and liver.
Arvapalli RK; Paturi S; Laurino JP; Katta A; Kakarla SK; Gadde MK; Wu M; Rice KM; Walker EM; Wehner P; Blough ER
Cardiovasc Toxicol; 2010 Jun; 10(2):108-16. PubMed ID: 20229123
[TBL] [Abstract][Full Text] [Related]
18. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.
Farmaki K; Tzoumari I; Pappa C
Blood Cells Mol Dis; 2011 Jun; 47(1):33-40. PubMed ID: 21531154
[TBL] [Abstract][Full Text] [Related]
19. Cardioprotective Potential of Iron Chelators and Prochelators.
Jansová H; Šimůnek T
Curr Med Chem; 2019; 26(2):288-301. PubMed ID: 28933303
[TBL] [Abstract][Full Text] [Related]
20. Ferroptosis inhibitor improves cardiac function more effectively than inhibitors of apoptosis and necroptosis through cardiac mitochondrial protection in rats with iron-overloaded cardiomyopathy.
Kumfu S; Sripetchwandee J; Thonusin C; Sumneang N; Maneechote C; Arunsak B; Chunchai T; Oo TT; Kongkaew A; Chattipakorn SC; Chattipakorn N
Toxicol Appl Pharmacol; 2023 Nov; 479():116727. PubMed ID: 37863361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
